Jazz Pharmaceuticals (JAZZ) Given a $208.00 Price Target at Piper Jaffray Companies
Piper Jaffray Companies set a $208.00 price target on Jazz Pharmaceuticals (NASDAQ:JAZZ) in a report published on Wednesday morning. The brokerage currently has a buy rating on the specialty pharmaceutical company’s stock.
A number of other research analysts have also issued reports on the company. Cantor Fitzgerald reaffirmed a buy rating and set a $201.00 target price on shares of Jazz Pharmaceuticals in a report on Tuesday. BidaskClub lowered Jazz Pharmaceuticals from a sell rating to a strong sell rating in a report on Wednesday, September 19th. Wells Fargo & Co reaffirmed a buy rating and set a $195.00 target price (up from $182.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, August 15th. Morgan Stanley lowered Jazz Pharmaceuticals from an overweight rating to an equal weight rating and set a $183.00 target price on the stock. in a report on Wednesday, July 11th. Finally, Zacks Investment Research lowered Jazz Pharmaceuticals from a hold rating to a sell rating in a report on Monday, July 16th. Three analysts have rated the stock with a sell rating, three have given a hold rating and fifteen have issued a buy rating to the company’s stock. Jazz Pharmaceuticals currently has an average rating of Buy and a consensus target price of $190.61.
Shares of JAZZ traded up $1.78 during trading hours on Wednesday, reaching $142.19. 1,743,725 shares of the company’s stock traded hands, compared to its average volume of 498,591. The firm has a market capitalization of $9.93 billion, a price-to-earnings ratio of 14.87, a price-to-earnings-growth ratio of 0.89 and a beta of 1.06. The company has a debt-to-equity ratio of 0.54, a quick ratio of 3.62 and a current ratio of 3.76. Jazz Pharmaceuticals has a twelve month low of $130.15 and a twelve month high of $184.00.
In related news, SVP Paul Treacy sold 1,309 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, August 10th. The stock was sold at an average price of $176.61, for a total value of $231,182.49. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Michael Patrick Miller sold 200 shares of Jazz Pharmaceuticals stock in a transaction dated Tuesday, August 14th. The stock was sold at an average price of $175.70, for a total value of $35,140.00. Following the completion of the transaction, the executive vice president now directly owns 25,572 shares in the company, valued at approximately $4,493,000.40. The disclosure for this sale can be found here. Insiders sold a total of 34,678 shares of company stock worth $5,959,173 in the last three months. 3.90% of the stock is currently owned by company insiders.
Institutional investors and hedge funds have recently modified their holdings of the stock. Stratos Wealth Partners LTD. purchased a new position in Jazz Pharmaceuticals in the 3rd quarter worth about $106,000. Tiverton Asset Management LLC purchased a new position in Jazz Pharmaceuticals in the 2nd quarter worth about $198,000. Moloney Securities Asset Management LLC purchased a new position in Jazz Pharmaceuticals in the 2nd quarter worth about $204,000. FDx Advisors Inc. purchased a new position in Jazz Pharmaceuticals in the 2nd quarter worth about $244,000. Finally, Cadence Capital Management LLC purchased a new position in Jazz Pharmaceuticals in the 3rd quarter worth about $263,000. 92.95% of the stock is currently owned by hedge funds and other institutional investors.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Recommended Story: Understanding Market Liquidity
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.